{"id":"W4362657687","doi":"10.1001/jamaoncol.2023.0147","title":"Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck","year":2023,"lang":"en","type":"article","venue":"JAMA Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Université de Montréal; University of Alberta","funders":"National Institute for Health and Care Research; Seagen; MacroGenics; Mirati Therapeutics; Kowa Company; Sanofi; EMD Serono; Rakuten Medical; Bristol-Myers Squibb; AstraZeneca; Pfizer; Coherus Biosciences","keywords":"Medicine; Nivolumab; Ipilimumab; Head and neck; Oncology; Head and neck squamous-cell carcinoma; Internal medicine; Metastatic melanoma; Basal cell; Expanded access; Head and neck cancer; Melanoma; Dermatology; Immunotherapy; Surgery; Radiation therapy; Cancer; Cancer research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002331538,0.0007688195,0.001868701,0.0004024004,0.0002374892,0.0009329133,0.000783428,0.001311221,0.003725452],"category_scores_gemma":[0.00261355,0.0004641226,0.001746486,0.0003161085,0.0007171452,0.0009812569,0.0003706179,0.002334398,0.0005953251],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001234586,"about_ca_system_score_gemma":0.001241795,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007332273,"about_ca_topic_score_gemma":0.002250591,"domain_scores_codex":[0.9991837,0.0004400535,0.00005940881,0.0001256155,0.00008878595,0.0001023968],"domain_scores_gemma":[0.9986249,0.0004422933,0.0004783872,0.00007074559,0.00007545149,0.0003081022],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9309397,0.007091633,0.003295821,0.0009253158,0.001445514,0.00003392239,0.00004728321,0.0009906586,0.004717929,0.00006815811,0.0006977327,0.04974633],"study_design_scores_gemma":[0.5668279,0.4050604,0.01889317,0.0001658906,0.002711168,0.0001006889,0.00004828125,0.001593964,0.002803612,0.0002326706,0.001525125,0.00003728865],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9894632,0.006488556,0.000231554,0.0004259865,0.0002980568,0.0009093476,0.0005690215,0.00004594988,0.001568299],"genre_scores_gemma":[0.9958894,0.001423358,0.000409818,0.0003551958,0.000204465,0.0005417311,0.0003546248,0.000007562454,0.0008139668],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003725452,"threshold_uncertainty_score":0.01246285,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05209509396336871,"score_gpt":0.3452510310749039,"score_spread":0.2931559371115352,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}